Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2003 1
2005 2
2006 1
2010 1
2013 2
2015 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Synergistic immunotherapy targeting cancer-associated anemia: prospects of a combination strategy.
Yuan T, Jia Q, Zhu B, Chen D, Long H. Yuan T, et al. Cell Commun Signal. 2023 May 19;21(1):117. doi: 10.1186/s12964-023-01145-w. Cell Commun Signal. 2023. PMID: 37208766 Free PMC article. Review.
Here, we review the possible mechanisms of cancer-induced anemia regarding decreased erythropoiesis and increased erythrocyte destruction, and cancer treatment-induced anemia. Moreover, we summarize the current paradigm for cancer-associated anemia treatment. …
Here, we review the possible mechanisms of cancer-induced anemia regarding decreased erythropoiesis and increased erythrocyte destruction, a …
ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.
Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, Tsunoda T, Hayes CN, Kumada H, Nakamura Y, Chayama K. Ochi H, et al. Gastroenterology. 2010 Oct;139(4):1190-7. doi: 10.1053/j.gastro.2010.06.071. Epub 2010 Jul 14. Gastroenterology. 2010. PMID: 20637204
RESULTS: We identified a variant, located upstream of the inosine triphosphate pyrophosphatase gene on chromosome 20p13 that is significantly associated with treatment-induced anemia (combined P = 6.0 10(-14)). Resequencing and fine-mapping revealed several s …
RESULTS: We identified a variant, located upstream of the inosine triphosphate pyrophosphatase gene on chromosome 20p13 that is significantl …
Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.
Smirne C, D'Avolio A, Bellan M, Gualerzi A, Crobu MG, Pirisi M. Smirne C, et al. Pharmacol Res Perspect. 2021 Aug;9(4):e00811. doi: 10.1002/prp2.811. Pharmacol Res Perspect. 2021. PMID: 34152088 Free PMC article.
Adverse events were reported in 142 patients (73.2%), but only 1.5% discontinued treatment. Eighty-eight subjects with treatment-induced anemia (mild: 34.5%, moderate: 7.7%, severe: 3.1%) had to reduce ribavirin dosage, but SVR rates were comparable to the we …
Adverse events were reported in 142 patients (73.2%), but only 1.5% discontinued treatment. Eighty-eight subjects with treatment-i …
Cisplatin-associated anemia: an erythropoietin deficiency syndrome.
Wood PA, Hrushesky WJ. Wood PA, et al. J Clin Invest. 1995 Apr;95(4):1650-9. doi: 10.1172/JCI117840. J Clin Invest. 1995. PMID: 7706473 Free PMC article.
Cisplatin-based therapy results in a cumulative anemia that is disproportionate to the effects on other blood cells. The severity of this treatment-induced anemia and the resultant transfusion requirement in cancer patients correlate with cisplatin-induced re …
Cisplatin-based therapy results in a cumulative anemia that is disproportionate to the effects on other blood cells. The severity of this …
ITPA gene variant may protect against anemia induced during pegylated interferon alfa and ribavirin combination treatment in Ukrainian patients with chronic hepatitis C.
Kucherenko A, Pampukha V, Bobrova I, Moroz L, Livshits L. Kucherenko A, et al. Tsitol Genet. 2015 Mar-Apr;49(2):38-41. Tsitol Genet. 2015. PMID: 26030972 Free article.
The aim of this study was to clarify the association between the inosine triphosphate pyrophosphatase (ITPA) gene variants and PEG-IFNalpha/RBV combination treatment induced anemia in chronic hepatitis C (CHC) Ukrainian patients. ...All study participants rec …
The aim of this study was to clarify the association between the inosine triphosphate pyrophosphatase (ITPA) gene variants and PEG-IFNalpha/ …
Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis.
Spiegel BM, Chen K, Chiou CF, Robbins S, Younossi ZM. Spiegel BM, et al. Clin Gastroenterol Hepatol. 2005 Oct;3(10):1034-42. doi: 10.1016/s1542-3565(05)00695-6. Clin Gastroenterol Hepatol. 2005. PMID: 16234051
BACKGROUND & AIMS: Treatment-induced anemia undermines the efficacy of antiviral therapy in hepatitis C by mandating ribavirin dose reduction and diminishing adherence to therapy. Erythropoietic growth factors (EGFs) may correct treatment-induce …
BACKGROUND & AIMS: Treatment-induced anemia undermines the efficacy of antiviral therapy in hepatitis C by mandatin …
Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients.
Spaan M, Groothuismink ZM, Koning L, Roomer R, Janssen HL, De Knegt RJ, Boonstra A. Spaan M, et al. Antiviral Res. 2013 Jun;98(3):469-75. doi: 10.1016/j.antiviral.2013.04.003. Epub 2013 Apr 11. Antiviral Res. 2013. PMID: 23583759
Moreover, we studied eight chronic HCV patients undergoing treatment with peg-IFN and ribavirin, who were administered EPO for treatment-induced anemia. Blood was collected before and 7 days after EPO injection. ...
Moreover, we studied eight chronic HCV patients undergoing treatment with peg-IFN and ribavirin, who were administered EPO for treatment …
Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.
Ahmed WH, Furusyo N, Zaky S, Eldin AS, Aboalam H, Ogawa E, Murata M, Hayashi J. Ahmed WH, et al. World J Gastroenterol. 2013 Mar 7;19(9):1387-95. doi: 10.3748/wjg.v19.i9.1387. World J Gastroenterol. 2013. PMID: 23538996 Free PMC article.
CONCLUSION: Rs1127354 ITPA polymorphism plays a decisive role in protecting against treatment-induced anemia and the need for RBV dose reduction in Egyptian HCV patients....
CONCLUSION: Rs1127354 ITPA polymorphism plays a decisive role in protecting against treatment-induced anemia and the ne …
11 results